Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,479 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The advent of biosimilar therapies in rheumatology--"O brave new world".
Scheinberg MA, Kay J. Scheinberg MA, et al. Among authors: kay j. Nat Rev Rheumatol. 2012 Jun 5;8(7):430-6. doi: 10.1038/nrrheum.2012.84. Nat Rev Rheumatol. 2012. PMID: 22664834 Review.
Biosimilars in rheumatology: current perspectives and lessons learnt.
Dörner T, Kay J. Dörner T, et al. Among authors: kay j. Nat Rev Rheumatol. 2015 Dec;11(12):713-24. doi: 10.1038/nrrheum.2015.110. Epub 2015 Aug 18. Nat Rev Rheumatol. 2015. PMID: 26282080 Review.
The changing landscape of biosimilars in rheumatology.
Dörner T, Strand V, Cornes P, Gonçalves J, Gulácsi L, Kay J, Kvien TK, Smolen J, Tanaka Y, Burmester GR. Dörner T, et al. Among authors: kay j. Ann Rheum Dis. 2016 Jun;75(6):974-82. doi: 10.1136/annrheumdis-2016-209166. Epub 2016 Mar 8. Ann Rheum Dis. 2016. PMID: 26964144 Free PMC article. Review.
The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016.
Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, Bathon JM, Buch MH, Burmester GR, Dougados M, Kay J, Mariette X, Breedveld FC, Kalden JR, Smolen JS, Furst DE. Winthrop KL, et al. Among authors: kay j. Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):69-76. Epub 2016 Aug 3. Clin Exp Rheumatol. 2016. PMID: 27586809
Biosimilars: implications for rheumatoid arthritis therapy.
Cohen S, Kay J. Cohen S, et al. Among authors: kay j. Curr Opin Rheumatol. 2017 May;29(3):260-268. doi: 10.1097/BOR.0000000000000379. Curr Opin Rheumatol. 2017. PMID: 28306596 Review.
Rituximab biosimilars.
Vital EM, Kay J, Emery P. Vital EM, et al. Among authors: kay j. Expert Opin Biol Ther. 2013 Jul;13(7):1049-62. doi: 10.1517/14712598.2013.787064. Epub 2013 Apr 22. Expert Opin Biol Ther. 2013. PMID: 23600760 Review.
Biosimilars in rheumatology: what the clinician should know.
Castañeda-Hernández G, González-Ramírez R, Kay J, Scheinberg MA. Castañeda-Hernández G, et al. Among authors: kay j. RMD Open. 2015 May 23;1(1):e000010. doi: 10.1136/rmdopen-2014-000010. eCollection 2015. RMD Open. 2015. PMID: 26509046 Free PMC article.
The Science Behind Biosimilars: Entering a New Era of Biologic Therapy.
Bridges SL Jr, White DW, Worthing AB, Gravallese EM, O'Dell JR, Nola K, Kay J, Cohen SB; American College of Rheumatology. Bridges SL Jr, et al. Among authors: kay j. Arthritis Rheumatol. 2018 Mar;70(3):334-344. doi: 10.1002/art.40388. Epub 2018 Feb 7. Arthritis Rheumatol. 2018. PMID: 29411547 No abstract available.
E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU. Visvanathan S, et al. Among authors: kay j. J Rheumatol. 2009 Jul;36(7):1371-9. doi: 10.3899/jrheum.080755. Epub 2009 Jun 1. J Rheumatol. 2009. PMID: 19487269 Clinical Trial.
Biosimilars: a regulatory perspective from America.
Kay J. Kay J. Arthritis Res Ther. 2011 May 12;13(3):112. doi: 10.1186/ar3310. Arthritis Res Ther. 2011. PMID: 21586106 Free PMC article.
1,479 results
Jump to page
Feedback